Peptide:MHC Binding Characterization for Off-Target Peptide Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying peptide:MHC binding polypeptides are inefficient and inaccurate, leading to off-target toxicity in cancer immunotherapy due to the inability to precisely identify and characterize off-target peptides that can bind to MHC molecules, posing a significant safety risk.
Innovation Solution
A method involving the use of peptide:MHC binding polypeptides, derived from T-cell receptors or antibody binding domains, to directly isolate and identify off-target peptides through affinity purification and mass spectrometry, reducing the need for cumbersome prediction algorithms and in vitro testing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If prediction algorithms and in vitro testing are used to identify peptide:MHC binding polypeptides, then identification can be performed, but the process is cumbersome, inefficient, and inaccurate leading to off-target toxicity
Solution Approach 1:
The patent extracts the peptide:MHC complex from the cellular context and directly presents it to T-cells for identification. This eliminates the need for prediction algorithms and in vitro testing by directly observing which T-cells bind to which peptide:MHC complexes in a simplified system
Solution Approach 2:
The patent introduces a simplified cellular system as an intermediary between prediction algorithms and final validation. This intermediary system directly presents peptide:MHC complexes to T-cells, providing accurate identification without the complexity of full in vitro testing
2Reliability
If comprehensive peptide screening is performed to identify off-target peptides, then off-target toxicity can be reduced, but the time and resources required increase significantly
Solution Approach 1:
The patent performs preliminary identification of peptide:MHC binding specificities using a simplified cellular system before conducting full safety assessments. This preliminary action identifies candidate off-target peptides that need further evaluation, reducing the overall time and resources required for comprehensive screening
3Measurement precision
If current methods are used to characterize peptide:MHC binding, then binding can be identified, but off-target peptides are missed leading to off-target toxicity in immunotherapy
Solution Approach 1:
The patent uses T-cells themselves to identify their own binding specificities by directly presenting peptide:MHC complexes to them. This self-service approach allows accurate identification of both on-target and off-target binding specificities, preventing off-target toxicity while maintaining binding precision
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for the sensitive and reliable identification of off-target peptides, significantly reducing the number of off-target peptides identified, thereby minimizing off-target toxicity and improving the specificity of cancer immunotherapy.
Implementation Method 1
contacting the sample with the polypeptide molecule, allowing the at least one peptide binding domain of the polypeptide molecule to bind, preferably specifically, to a peptide:MHC complex
Implementation Method 2
identifying the amino acid sequence of the peptide, preferably by mass spectrometry
Data Source
AI summary
The present invention relates to a method for the characterization of peptide:MHC binding polypeptides, e.g. by mass spectrometry and an analysis of the recognized peptide space, i.e. in order to identify peptides that can be bound in the context of their presentation by MHC, and those who cannot be bound.